Risk of intracranial hemorrhage from statin use in Asians: A nationwide cohort study

Circulation

Volumn 131, Issue 23, 2015, Pages 2070-2078

  Chang, Chia Hsuin ^a,b,c   Lin, Chin Hsien ^a   Caffrey, James L ^d   Lee, Yen Chieh ^c,e   Liu, Ying Chun ^c   Lin, Jou Wei ^a,b   Lai, Mei Shu ^c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^e CATHAY GENERAL HOSPITAL   (Taiwan)

Author keywords

Cohort studies; Hydroxymethylglutaryl CoA reductase inhibitors; Intracranial hemorrhages; Taiwan

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; ASIAN; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DRUG USE; FEMALE; FOLLOW UP; HAZARD RATIO; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; TAIWAN; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; DOSE RESPONSE; HYPERCHOLESTEROLEMIA; INCIDENCE; INTRACRANIAL HEMORRHAGES; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR;

CARDIOVASCULAR DISEASES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INCIDENCE; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN;

EID: 84936138660     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.114.013046     Document Type: Article

References (48)

1. Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral hemorrhage. N Engl J Med. 2001;344:1450-1460. doi: 10.1056/NEJM200105103441907.
2. Noda H, Iso H, Irie F, Sairenchi T, Ohtaka E, Doi M, Izumi Y, Ohta H. Lowdensity lipoprotein cholesterol concentrations and death due to intraparenchymal hemorrhage: the Ibaraki Prefectural Health Study. Circulation. 2009;119:2136-2145. doi: 10.1161/CIRCULATIONAHA.108.795666.
3. Wang X, Dong Y, Qi X, Huang C, Hou L. Cholesterol levels and risk of hemorrhagic stroke: a systematic review and meta-analysis. Stroke. 2013;44:1833-1839. doi: 10.1161/STROKEAHA.113.001326.
4. Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, Longstreth WT Jr, Psaty BM. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology. 2004;63:1868-1875.
5. Konishi M, Iso H, Komachi Y, Iida M, Shimamoto T, Jacobs DR Jr, Terao A, Baba S, Sankai T, Ito M. Associations of serum total cholesterol, different types of stroke, and stenosis distribution of cerebral arteries. The Akita Pathology Study. Stroke. 1993;24:954-964.
6. Vergouwen MD, de Haan RJ, Vermeulen M, Roos YB. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke. 2008;39:497-502. doi: 10.1161/STROKEAHA.107.488791.
7. Flaster M, Morales-Vidal S, Schneck MJ, Biller J. Statins in hemorrhagic stroke. Expert Rev Neurother. 2011;11:1141-1149. doi: 10.1586/ern.11.101.
8. Goldstein LB, Amarenco P, Lamonte M, Gilbert S, Messig M, Callahan A, Hennerici M, Sillesen H, Welch KM; SPARCLInvestigators. Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Stroke. 2008;39:2444-2448. doi: 10.1161/STROKEAHA.107.513747.
9. Serebruany VL, Malinin AI, Hennekens CH. Statins increase risk of hemorrhagic stroke by inhibition of the PAR-1 receptor. Cerebrovasc Dis. 2007;24:477-479. doi: 10.1159/000108923.
10. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757-767. doi: 10.1016/S0140-6736(04)15690-0.
11. Hackam DG, Woodward M, Newby LK, Bhatt DL, Shao M, Smith EE, Donner A, Mamdani M, Douketis JD, Arima H, Chalmers J, MacMahon S, Tirschwell DL, Psaty BM, Bushnell CD, Aguilar MI, Capampangan DJ, Werring DJ, De Rango P, Viswanathan A, Danchin N, Cheng CL, Yang YH, Verdel BM, Lai MS, Kennedy J, Uchiyama S, Yamaguchi T, Ikeda Y, Mrkobrada M. Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation. 2011;124:2233-2242. doi: 10.1161/CIRCULATIONAHA.111.055269.
12. McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke. 2012;43:2149-2156. doi: 10.1161/STROKEAHA.112.655894.
13. Meier N, Nedeltchev K, Brekenfeld C, Galimanis A, Fischer U, Findling O, Remonda L, Schroth G, Mattle HP, Arnold M. Prior statin use, intracranial hemorrhage, and outcome afteRintra-arterial thrombolysis for acute ischemic stroke. Stroke. 2009;40:1729-1737. doi: 10.1161/STROKEAHA.108.532473.
14. Gorelick PB. Statin use and intracerebral hemorrhage: evidence for safety in recurrent stroke prevention? Arch Neurol. 2012;69:13-16. doi: 10.1001/archneurol.2011.234.
15. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 suppl 2):S1-45. doi: 10.1161/01.cir.0000437738.63853.7a.
16. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol. 2009;8:355-369. doi: 10.1016/S1474-4422(09)70025-0.
17. van Asch CJ, Luitse MJ, Rinkel GJ, van der TweeLi, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010;9:167-176. doi: 10.1016/S1474-4422(09)70340-0.
18. Tsai CF, Thomas B, Sudlow CL. Epidemiology of stroke and its subtypes in Chinese vs white populations: a systematic review. Neurology. 2013;81:264-272. doi: 10.1212/WNL.0b013e31829bfde3.
19. Group ESaCHDCR. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet. 1998;352:1801-1807.
20. WHO Collaborating Centre for Drug Statistics Methodology. Defined daily dose: definition and general considerations. http://www.whocc.no/ddd/definition-and-general-considera/Accessed July 29, 2014.
21. Stricker BH, Stijnen T. Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies. Eur J Epidemiol. 2010;25:245-251. doi: 10.1007/s10654-010-9451-7.
22. Okin PM, Hille DA, Wiik BP, Kjeldsen SE, Lindholm LH, Dahlöf B, Devereux RB. In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study. Diabet Med. 2013;30:1189-1197. doi: 10.1111/dme.12213.
23. Zanchetti A, Hennig M, Hollweck R, Bond G, Tang R, Cuspidi C, Parati G, Facchetti R, Mancia G. Baseline values but not treatment-induced changes in carotid intima-media thickness predict incident cardiovascular events in treated hypertensive patients: findings in the European Lacidipine Study on Atherosclerosis (ELSA). Circulation. 2009;120:1084-1090. doi: 10.1161/CIRCULATIONAHA.108.773119.
24. Andrade SE, Harrold LR, Tjia J, Cutrona SL, Saczynski JS, Dodd KS, Goldberg RJ, Gurwitz JH. A systematic review of validated methods foRidentifying cerebrovascular accident or transient ischemic attack using administrative data. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):100-128. doi: 10.1002/pds.2312.
25. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58:323-337. doi: 10.1016/j.jclinepi.2004.10.012.
26. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer-Verlag; 2000.
27. Arbogast PG, Kaltenbach L, Ding H, Ray WA. Adjustment for multiple cardiovascular risk factors using a summary risk score. Epidemiology. 2008;19:30-37. doi: 10.1097/EDE.0b013e31815be000.
28. Arbogast PG, Ray WA. Performance of disease risk scores, propensity scores, and traditional multivariable outcome regression in the presence of multiple confounders. Am J Epidemiol. 2011;174:613-620. doi: 10.1093/aje/kwr143.
29. Arbogast PG, Ray WA. Use of disease risk scores in pharmacoepidemiologic studies. Stat Methods Med Res. 2009;18:67-80. doi: 10.1177/0962280208092347.
30. Glynn RJ, Gagne JJ, Schneeweiss S. Role of disease risk scores in comparative effectiveness research with emerging therapies. Pharmacoepidemiol Drug Saf. 2012;21(suppl 2):138-147. doi: 10.1002/pds.3231.
31. Goldstein LB, Samsa GP, Matchar DB, Horner RD. Charlson Index comorbidity adjustment foRischemic stroke outcome studies. Stroke. 2004;35:1941-1945. doi: 10.1161/01.STR.0000135225.80898.1c.
32. Lee YC, Lin CH, Wu RM, Lin JW, Chang CH, Lai MS. Antihypertensive agents and risk of Parkinson's disease: a nationwide cohort study. PLoS One. 2014;9:e98961. doi: 10.1371/journal.pone.0098961.
33. Chang CH, Lin JW, Chiu FC, Caffrey JL, Wu LC, Lai MS. Effect of radiofrequency catheter ablation for atrial fibrillation on morbidity and mortality: a nationwide cohort study and propensity score analysis. Circ Arrhythm Electrophysiol. 2014;7:76-82. doi: 10.1161/CIRCEP.113.000597.
34. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19:117-125. doi: 10.1111/j.1472-8206.2004.00299.x.
35. Mascitelli L, Pezzetta F. Concerns about efficacy and safety of statins in the prevention of stroke. Intern Med J. 2009;39:209-210. doi: 10.1111/j.1445-5994.2008.01891.x.
36. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E; PROVE IT-TIMI 22 Investigators. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005;46:1411-1416. doi: 10.1016/j.jacc.2005.04.064.
37. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681.
38. Amarenco P, Bogousslavsky J, Callahan AS, Goldstein L, Hennerici M, Sillsen H, Welch MA, Zivin J; SPARCLInvestigators. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study. Cerebrovasc Dis. 2003;16:389-395.
39. Seshasai SR, Ray KK. Intensive statin therapy in coronary artery disease: is lower cholesterol better and safe? Future Cardiol. 2009;5:129-139. doi: 10.2217/14796678.5.2.129.
40. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581-590.
41. Ballantyne CM, Riegger G, Moore N, Saia F, Serruys PW. Fluvastatin reduces cardiac mortality in patients with coronary heart disease. Cardiovasc Drugs Ther. 2004;18:67-75. doi: 10.1023/B:C ARD.0000025757.14093.e0.
42. Murphy SA, Cannon CP, Wiviott SD, de Lemos JA, Blazing MA, McCabe CH, Califf RM, Braunwald E. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in MyocardiaLinfarction 22 trials). Am J Cardiol. 2007;100:1047-1051. doi: 10.1016/j.amjcard.2007.04.053.
43. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207. doi: 10.1056/NEJMoa0807646.
44. Gotto AM Jr. Statin therapy and the elderly: SAGE advice? Circulation. 2007;115:681-683. doi: 10.1161/CIRCULATIONAHA.106.678300.
45. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-1630.
46. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterollowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-2016.
47. Suzuki K, Izumi M, Sakamoto T, Hayashi M. Blood pressure and total cholesterol level are critical risks especially for hemorrhagic stroke in Akita, Japan. Cerebrovasc Dis. 2011;31:100-106. doi: 10.1159/000321506.
48. Woo D, Kissela BM, Khoury JC, Sauerbeck LR, Haverbusch MA, Szaflarski JP, Gebel JM, Pancioli AM, Jauch EC, Schneider A, Kleindorfer D, Broderick JP. Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study. Stroke. 2004;35:1360-1364. doi: 10.1161/01.STR.0000127786.16612.A4.